A trial of neoadjuvant dastanib by The Hoosier Oncology Group was well tolerated and further showed a marked decrease in tumor phosphorylated SRC Family Kinase (SFK) expression levels but failed to show changes in cell proliferation [31, 32]. This evidence concerns the gene SRC and neoplasm.